& # 39; The press release of this initial opinion, which must be considered confidential, is harmful to employees, customers and shareholders of the & # 39 ;, management indicates.
In this first recommendation, the Transparency Committee makes an unfavorable recommendation to maintain the health insurance of homopathic medicines.
The current evaluation procedure stipulates that the Boiron Laboratoires have 10 days after receiving this first recommendation to submit written comments or to submit a request to the HAS.
This procedure allows laboratories to present their arguments regarding the benefits of the treatment of homeopathic medicines. At the end of this procedure, the HAS will issue a final opinion that is passed on for decision by the Minister of Solidarity and Health & specifies the group.
& # 39; Offer of shares suspended Thursday May 16, 2019 due to the dissemination of confidential information by a media, Monday 20 May 2019 resumed the opening of the Exchange & # 39; adds management.
Copyright (c) 2019 CercleFinance.com. All rights reserved.